Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

ABSTRACT:

Introduction

Genomic aberrations involving the erb-b2 receptor tyrosine kinase 2 gene (ERBB2) are driver oncogenes in approximately 2% of lung adenocarcinomas. However, the use of daily dosing of ERBB2 tyrosine kinase inhibitors (TKIs)-including afatinib-has been fraught with plasma concentrations that barely achieve preclinical model inhibition, significant patient-reported toxicities, and limited clinical activity. We hypothesized that alternative dosing strategies could improve tolerability and efficacy.

Methods

We profiled lung cancer cell lines against TKIs and retrospectively evaluated the toxicity of and response to pulse afatinib (280 mg once weekly) in lung cancers with ERBB2 mutations.

Results

An ERBB2 exon 20 insertion-mutated lung cancer cell line had a 50

SUBMITTER: Costa DB 

PROVIDER: S-EPMC4877224 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature